# Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

> **NCT05616923** · PHASE1 · COMPLETED · sponsor: **Albany Research Institute, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Rosacea, Erythematotelangiectatic

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT05616923
- **Lead sponsor:** Albany Research Institute, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05616923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05616923, "Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05616923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*